[Market Focus] IMBDx Surges as Market Cap Nears 11 Trillion Won; Anticipation Grows for Emergence of Global Liquid Biopsy Leader

The stock price of IMBDx, a leader in precision oncology, is on the rise. News that the company has opened a new chapter in personalized treatment for patients appears to be influencing its share price. On this day, IMBDx officially launched 'AlphaLiquid 100 ver 3.0' (code name: CancerDx200), an upgraded version of its flagship liquid biopsy-based genomic profiling product, AlphaLiquid 100, which has significantly expanded its panel of analyzed genes from 118 to 192.

Among global frontrunners, Guardant Health's corporate value reaches 11.5638 trillion won. There are expectations that, with IMBDx's strengthened technological competitiveness and overseas expansion, the company could develop a growth story similar to that of Guardant Health.

As of 11:46 a.m. on September 3, IMBDx was trading at 9,140 won, up 12.56% from the previous day.

The upgraded product not only incorporates all key biomarkers approved by the United States Food and Drug Administration (FDA), but also adds a large number of essential genes for prescription decisions of the latest anticancer drugs in various solid tumors such as prostate, lung, and pancreatic cancers. By including genes targeted in clinical trials led by global pharmaceutical companies, the product ensures broader clinical trial opportunities and improved access to the latest therapies for domestic patients.

By enhancing biomarkers that predict immunotherapy response and genes related to drug resistance, medical professionals can now develop more precise, individualized treatment strategies for each patient. This translates into personalized medicine benefits that reduce unnecessary treatments and increase the likelihood of successful outcomes for patients.

CancerDx200 is significant not only for expanding the number of analytes but also for improving overall test quality. By adopting the latest analysis technology and rigorous quality management systems, IMBDx has raised sensitivity, specificity, and reproducibility to world-class levels while minimizing the possibility of misdiagnosis. Furthermore, the test cost remains unchanged, allowing patients to access more genetic information without additional financial burden.

Cha Yongjun, Chief Medical Officer at IMBDx, stated, "It is an innovation that both patients and healthcare professionals can feel, as we have nearly doubled the number of analyzed genes while maintaining the selective reimbursement benefit," and added, "Through this launch, we aim to enhance treatment accessibility for domestic solid tumor patients and lead the global precision medicine paradigm."

AlphaLiquid 100 ver 3.0 (CancerDx200) offers patients more than double the benefits at the same cost, and provides healthcare professionals with a powerful decision-making tool that reflects the latest global research and treatment guidelines. IMBDx expects this new product to become a turning point that will radically transform the cancer treatment landscape in Korea.

By the end of this year, IMBDx plans to sequentially introduce liquid biopsy products dedicated to prostate and breast cancers, as well as the large-scale research panel AlphaLiquid 1000. The company is also expanding its scope beyond liquid biopsy to tissue-based cancer genomic analysis, and aims to further solidify its global leadership in precision medicine solutions through the minimal residual disease (MRD) test 'CancerDetect' and the tissue whole exome-based product 'CancerProfiler.'

Kim Seungjun, a researcher at the Korea IR Council, commented, "It is noteworthy that IMBDx has established a full-cycle cancer diagnostic pipeline, spanning from precision diagnosis (AlphaLiquid series) to early detection (CancerFind) and residual cancer (MRD) monitoring (CancerDetect). The structure in which a single company operates a full-cycle diagnostic product lineup based on the same technology platform is rare among domestic companies."

He added, "This aligns with the direction pursued by global leaders such as Grail in the United States and Guardant Health. Not only are there significant technological and clinical synergies, but the operational efficiency between products and the potential for commercial scaling up are also very high, giving IMBDx a structurally differentiated position."

He further noted, "The AlphaLiquid platform is not just a precision diagnostic product with technological superiority, but is becoming a core growth axis capable of genuine global scaling up through entry into global clinical trials and expansion of distribution channels." He also predicted, "If multinational approvals and partner-based commercialization accelerate, this platform will provide direct leverage to the company's corporate value."

Researcher Kim explained, "AlphaLiquid 100 is a next-generation sequencing (NGS)-based panel test that can analyze genetic mutations in blood with high sensitivity," and introduced, "It has superior genetic information detection capability compared to Guardant360 CDx by Guardant Health in the United States, which covers 74 genes."

The global liquid biopsy market continues to grow rapidly. According to global market research firm Grand View Research, the market is expected to expand from approximately 11.9 billion dollars in 2024 to around 22.9 billion dollars by 2030, representing a compound annual growth rate (CAGR) of about 11.5%.